Peptide education
Palopegteriparatide
Yorvipath · TransCon PTH
Palopegteriparatide is a long-acting prodrug that releases an active fragment of parathyroid hormone. The U.S. prescription product Yorvipath treats adults with hypoparathyroidism, a condition in which too little parathyroid hormone disrupts calcium regulation.
Yorvipath is a once-daily injection for adults with hypoparathyroidism. Its dose and any changes to calcium or active vitamin D are guided by blood-calcium results, because both high and low calcium can be serious.
Overview
Quick answer
Yorvipath is not the same product as full-length PTH (1-84) or an osteoporosis injection. The medicines differ in formulation, release characteristics, dose, and labeling.
What does Yorvipath treat?
It is labeled for adults with hypoparathyroidism. It was not studied for acute post-surgical hypoparathyroidism, and its titration scheme was evaluated after calcium was brought to the label's starting threshold.
How is the dose chosen?
The U.S. label starts at 18 mcg under the skin once daily. The prescriber adjusts the dose in 3 mcg steps according to calcium results, within a labeled range of 6 to 30 mcg daily. The label calls for one injection per day.
Can calcium and active vitamin D always be stopped?
Not automatically. Treatment and supplements are adjusted together according to calcium levels. Some people may still need calcium for dietary needs or require additional treatment when the maximum labeled dose is insufficient.
What did PaTHway measure?
The trial combined normal blood calcium, reduced dependence on conventional calcium and active vitamin D, and stable study-drug dosing into one outcome. The publication and U.S. label use different supplement, missing-data, and study-dose criteria.
Evidence
Evidence snapshot
The label excludes evidence for acute post-surgical hypoparathyroidism.
At 26 weeks, the published PaTHway composite was met by 48 of 61 treated participants versus one of 21 on placebo.
The label analysis excluded as-needed supplements and missing supplement data in the final four weeks and counted doses above 30 mcg daily during the trial as nonresponse.
Calcium can change with treatment initiation, dose changes, or interruption, and serious events can occur.
Claims
Common claims vs evidence
| Claim | Human evidence | Verdict |
|---|---|---|
| Yorvipath can reduce reliance on conventional supplements for some adults. | In the published 26-week PaTHway analysis, 48 of 61 participants receiving palopegteriparatide met the combined endpoint versus one of 21 receiving placebo. The endpoint required normal blood calcium, no scheduled active vitamin D, an average scheduled calcium dose of at most 600 mg daily, and no study-drug dose increase in the preceding four weeks. It allowed as-needed calcium and active vitamin D on up to seven days each during those four weeks. | The result applies to the trial's combined outcome. It does not mean every participant stopped all calcium or that supplements should be changed without monitoring. |
| The label and publication report the same response percentage. | The publication reported 48 of 61 treated participants meeting its composite. The U.S. label reported 42 of 61 under an analysis that excluded as-needed calcium or active vitamin D and missing supplement data during the final four weeks. It also counted any study-drug dose above 30 mcg per day during the blinded period as nonresponse. | Both figures describe the same study using different response criteria. |
| A missed or interrupted treatment can affect calcium. | The label warns that serious hypocalcemia can occur and that the risk is highest with abrupt discontinuation. Hypercalcemia can also occur, including during dose initiation or increases. | Treatment interruptions and symptoms need prompt clinical attention. |
Bottom line
Main takeaway
Hypoparathyroidism affects calcium balance. Yorvipath supplies a long-acting source of active PTH, with monitoring to keep calcium in range.
The dose, supplement plan, lab schedule, and response to missed treatment are connected parts of care.
Compare the published PaTHway composite with the U.S. label's supplement, missing-data, and dose criteria before comparing percentages.
Identity
What it is
Palopegteriparatide is a prodrug of PTH (1-34) attached to a carrier that releases the active hormone over time.
The U.S. product is an adjustable, single-patient-use pen for subcutaneous injection.
Use context
Routes, doses, and cycle patterns
Yorvipath dosing and the calcium and active vitamin D plan are adjusted together using blood-calcium results.
Human studies and product labels
Yorvipath U.S. label
- Purpose
- Adult hypoparathyroidism
- Context
- U.S. prescription label
- Route
- Subcutaneous injection in the abdomen or front of the thigh
- Amount
- Starting dose 18 mcg, individualized range 6 to 30 mcg
- Frequency
- One injection once daily
Before starting, the label calls for normal vitamin D and albumin-corrected blood calcium of at least 7.8 mg/dL. Doses are adjusted in 3 mcg steps; the label gives separate rules for adjusting supplements.
PaTHway trial
- Purpose
- Calcium control and conventional-therapy requirements
- Context
- Published study regimen
- Route
- Subcutaneous
- Amount
- Initially 18 mcg, subsequently titrated
- Frequency
- Once daily
- Duration
- 26-week blinded period
Participants also received calcium and active vitamin D adjusted through the study algorithm.
What varies
- The label calls for blood-calcium measurement 7 to 10 days after the first dose and after changes to Yorvipath, calcium, or active vitamin D. Once a maintenance dose is reached, it specifies checks at least every 4 to 6 weeks.
- Before first use the pen is refrigerated. After first use, the label allows room-temperature storage below 30 C for 14 days, then disposal of the pen.
- Symptoms of low calcium can include tingling and muscle cramps; the label also lists abnormal heart rhythms and seizures among possible symptoms.
Research
Research evidence
PaTHway was a 26-week placebo-controlled trial in adults with chronic hypoparathyroidism after optimization of conventional treatment.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| PaTHway, published analysis | 84 randomized adults with chronic hypoparathyroidism, with 82 receiving study treatment | Randomized, double-blind, placebo-controlled | Initial 18 mcg daily, then titrated with conventional therapy | Composite met by 48 of 61 treated participants versus one of 21 placebo recipients | Manufacturer-funded, 26-week blinded comparison; supplement, missing-data, and dose criteria differ from the U.S. label analysis | Controlled composite biochemical and supplement outcome |
| U.S. label analysis of PaTHway | 61 treated participants and 21 placebo recipients | Label analysis of the randomized study | The label excludes as-needed supplements and missing supplement data in the final four weeks and counts doses above 30 mcg per day during the trial as nonresponse | Composite met by 42 of 61 treated participants versus one of 21 placebo recipients | Endpoint definition is narrower than the publication's composite | Product-specific regulatory evidence |
Cautions
Safety and unknowns
- Yorvipath is contraindicated in people with a history of severe hypersensitivity to palopegteriparatide or any ingredient in the product.
- Serious hypercalcemia and hypocalcemia can occur. Abruptly stopping treatment can lead to low calcium, so interruption and symptoms need clinical follow-up.
- The label warns about potential osteosarcoma risk based on findings with PTH analogs in rats and advises against use in certain people with elevated baseline risk.
- Serious hypersensitivity reactions, dizziness on standing, and interactions affected by blood calcium, including digoxin toxicity, are listed precautions.
Product quality
Product identity and quality
Yorvipath is a specific prefilled pen with product-specific doses and a 14-day in-use period.
Pen strength
Different pens deliver different labeled dose options.
Storage
The label distinguishes refrigeration before use from storage after first use.
Other medicines and supplements
Changes to calcium and active vitamin D can change blood-calcium levels.
Mechanism
How it is proposed to work
The medicine releases active PTH, helping regulate blood calcium in a condition where the body makes too little of the hormone.
PTH (1-34) interacts with PTH receptors involved in calcium and phosphate regulation; the prodrug is designed to extend active hormone exposure.
FAQ
Common questions
Can calcium supplements be stopped without monitoring?
No. The label ties changes in calcium or active vitamin D to blood-calcium monitoring and individualized clinical supervision.
Details
Technical details
Sources
References
- 1.
DailyMed. Yorvipath prescribing information
U.S. adult indication, dose and calcium monitoring, product handling, and safety.
- 2.
doi:10.1002/jbmr.4726 PMID:36271471 NCT04701203
Published 26-week randomized trial; the U.S. label uses different supplement, missing-data, and dose criteria in its response analysis.
- 3.
FDA. Natpara prescribing information
Archived U.S. Natpara label, used to distinguish the products.